Search

Mucopolysaccharidosis (MPS IIIA) mice have increased lung compliance and airway resistance, decreased diaphragm strength, and no change in alveolar structure

Mucopolysaccharidosis type IIIA (MPS IIIA) is characterized by neurological and skeletal pathologies caused by reduced activity of the lysosomal hydrolase, sulfamidase, and the subsequent primary accumulation of undegraded heparan sulfate (HS). Respiratory pathology is considered secondary in MPS IIIA and the mechanisms are not well understood. 

Wal-yan Scientific Retreat: Fostering Collaborative Excellence

The Wal-yan Respiratory Research Centre's dedicated team members, along with special guests, embarked on a journey to Wadjemup (Rottnest Island) on 9 and 10 November. 

Research into chronic lung disease in Indigenous children and a novel RSV treatment boosted thanks to WACRF grants

Wal-yan Respiratory Research Centre researchers will use almost $1.2 million in WA Child Research Fund grants to determine why Indigenous children develop bronchiectasis at such high rates after contracting bronchiolitis, and to test a promising novel treatment for respiratory syncytial virus (RSV).

Seven innovative lung health research projects supported by Wal-yan Centre funding

Seven innovative lung health research projects have received funding support as the 2023 Wal-yan Respiratory Research Centre Strategic Inspiration Projects.

Keelan has ‘survived and thrived’, thanks to research

Ten-year-old Keelan Mullins is known to his mum Clare Hindle as her ‘miracle baby’. Keelan was born in March 2013 at 26 weeks’ gestation and weighing just 1096 grams.